Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients? is a research paper published in Translational Cancer Research (2020). On theSindex it has a DataRank of 0.165. It has been cited 2 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: P30 CA016056
NCI NIH HHS
Grant: R01 CA160688
National Institutes of Health
Grant: 5P30CA016056-40
Roswell Park Cancer Institute Cancer Center Support Grant
National Institutes of Health
Grant: 5R01CA160688-03
Sphingosine-1-phosphate in breast cancer progression and lymphangiogenesis
FWCI
0.15
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords